PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Summerer, I. ; Unger, K. ; Braselmann, H. ; Schuettrumpf, L. ; Maihoefer, C. ; Baumeister, P. ; Kirchner, T.* ; Niyazi, M. ; Sage, E.H.* ; Specht, H.M.* ; Multhoff, G. ; Mörtl, S. ; Belka, C. ; Zitzelsberger, H.

Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients.

Br. J. Cancer 113, 76-82 (2015)
Verlagsversion DOI PMC
Closed
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
BACKGROUND: The prediction of therapy response in head and neck squamous cell cancer (HNSCC) requires biomarkers, which are also a prerequisite for personalised therapy concepts. The current study aimed to identify therapy-responsive microRNAs (miRNAs) in the circulation that can serve as minimally invasive prognostic markers for HNSCC patients undergoing radiotherapy. METHODS: We screened plasma miRNAs in a discovery cohort of HNSCC patients before therapy and after treatment. We further compared the plasma miRNAs of the patients to age- and sex-matched healthy controls. All miRNAs identified as biomarker candidates were then confirmed in an independent validation cohort of HNSCC patients and tested for correlation with the clinical outcome. RESULTS: We identified a signature of eight plasma miRNAs that differentiated significantly (P=0.003) between HNSCC patients and healthy donors. MiR-186-5p demonstrated the highest sensitivity and specificity to classify HNSCC patients and healthy individuals. All therapy-responsive and patient-specific miRNAs in plasma were also detectable in tumour tissues derived from the same patients. High expression of miR-142-3p, miR-186-5p, miR-195-5p, miR-374b-5p and miR-574-3p in the plasma correlated with worse prognosis. CONCLUSIONS: Circulating miR-142-3p, miR-186-5p, miR-195-5p, miR-374b-5p and miR-574-3p represent the most promising markers for prognosis and therapy monitoring in the plasma of HNSCC patients. We found strong evidence that the circulating therapy-responsive miRNAs are tumour related and were able to validate them in an independent cohort of HNSCC patients.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.836
1.519
87
101
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Biomarker ; Circulating Non-coding Rna ; Head And Neck Cancer ; Prognosis ; Radiochemotherapy ; Radiotherapy Outcome; Squamous-cell Carcinoma; Human-papillomavirus; Breast-cancer; Radiation-therapy; Esophageal Cancer; Prostate-cancer; Mirnas; Chemoradiotherapy; Mir-142-3p; Markers
Sprache englisch
Veröffentlichungsjahr 2015
HGF-Berichtsjahr 2015
ISSN (print) / ISBN 0007-0920
e-ISSN 1532-1827
Zeitschrift British Journal of Cancer BJC
Quellenangaben Band: 113, Heft: 1, Seiten: 76-82 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Begutachtungsstatus Peer reviewed
Institut(e) Translational Metabolic Oncology (IDC-TMO)
Institute of Radiation Medicine (IRM)
Institute of Radiation Biology (ISB)
POF Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
30203 - Molecular Targets and Therapies
30202 - Environmental Health
Forschungsfeld(er) Radiation Sciences
PSP-Element(e) G-521800-001
G-501000-001
G-501390-001
G-500200-001
PubMed ID 26057452
DOI 10.1038/bjc.2015.111
WOS ID WOS:000357188500011
Scopus ID 84934444721
Scopus ID 84930800368
Erfassungsdatum 2015-06-11
[➜Korrektur melden]